Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2025 U.S. Biopharma Recap

The summer biopharma turned pretty (again).

Biopharma bounced back in the third quarter, powered by the year’s first rate cut, a steady run of big M&A, and a wave of positive clinical data, especially from the latest IPO class. Both the XBI and NBI are well above their April lows and ended the quarter up 11.3% and 13.2% year-to-date, with the XBI closing the quarter at $100, helping set the stage for a healthier financing backdrop.

Public markets shook off the doldrums with activity rebounding sharply from Q2’s multiyear lows. The first IPO since February broke the sector’s longest drought since the Great Financial Crisis, and private financings showed early signs of recovery with 56 deals—seven of which were crossover rounds—as investors remain cautious in a still-narrow IPO window.

M&A, meanwhile, remained the brightest spot with six public all-cash deals over $1 billion helping to return $22 billion in capital and pushing 2025’s total deal value past all of 2024.

William Blair’s biopharma team shares additional perspectives on what to expect for the remainder of the year and heading into 2026.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Matt Zimmer Discusses Deal Outlook, PE Strategy, Secondaries on Bloomberg TV

    Global Head of Investment Banking Matt Zimmer recently appeared on Bloomberg TV’s “Open Interest” program.

    Read more
  • The Pet Supplements Industry Is Booming and Requires More Capacity and Capabilities

    The pet supplements industry is on track for strong continued growth. Meeting future demand will require both additional capacity and enhanced capabilities to stay ahead of intensifying competition—creating opportunities for investors.

    Read more
  • William Blair Serves as Exclusive Financial Advisor to Vantaca in its Minority Growth Investment From Cove Hill Partners

    William Blair acted as the exclusive financial advisor to Vantaca in connection with its $300-plus million minority growth investment from Cove Hill Partners at a $1.25 billion valuation.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures